Slingshot members are tracking this event:

Ardelyx'S Plans to Initiate The Second Phase 3 Study of Tenapanor for The Treatment Of Hyperphosphatemia in ESRD Patients on Dialysis in Mid-2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
ARDX Community voting in process
KERX Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 15, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Tenapanor, End-stage Renal Disease, Esrd, Hyperphosphatemia